Compare GAIA & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | MNOV |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 72.7M |
| IPO Year | 1999 | 2005 |
| Metric | GAIA | MNOV |
|---|---|---|
| Price | $3.86 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $7.00 |
| AVG Volume (30 Days) | ★ 100.6K | 91.9K |
| Earning Date | 11-03-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,622,000.00 | $257,917.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $11.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.80 | N/A |
| 52 Week Low | $2.93 | $1.13 |
| 52 Week High | $6.39 | $2.06 |
| Indicator | GAIA | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 66.96 |
| Support Level | $3.65 | $1.43 |
| Resistance Level | $3.99 | $1.52 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 59.18 | 93.59 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.